Cargando…
Genomic Abnormalities as Biomarkers and Therapeutic Targets in Acute Myeloid Leukemia
SIMPLE SUMMARY: AML is a heterogenous malignancy with a variety of underlying genomic abnormalities. Some of the genetic aberrations in AML have led to the development of specific inhibitors which were approved by the Food and Drug Administration (FDA) and are currently used to treat eligible patien...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533805/ https://www.ncbi.nlm.nih.gov/pubmed/34680203 http://dx.doi.org/10.3390/cancers13205055 |